MFM Physician Discussion Series

Potter Syndrome
& Potter Sequence

Pathophysiology · Diagnosis · Prognosis · Emerging Therapies

Maternal-Fetal Medicine | ACOG · SMFM · RAFT Trial 2023 | DoctorsWhoCode.blog
Terminology

Syndrome vs. Sequence

Potter Syndrome

  • Classic / "true" Potter
  • Bilateral renal agenesis (BRA)
  • Described by Edith Potter, 1946
  • Specific etiology — BRA only
  • Prevalence: ~1 in 3,000 births
  • Male predominance

Potter Sequence

  • Oligohydramnios sequence
  • Any cause of severe oligohydramnios
  • Preferred modern dysmorphology term
  • Single initiating event → cascade
  • Renal & non-renal etiologies
  • Technically more precise

"Sequence" is preferred because findings arise from one initiating event, not a shared genetic cause.

Etiology

Osathanondh & Potter Classification

Type Diagnosis Mechanism Key Feature
I ARPKD (infantile PKD) Fusiform dilation of collecting ducts Bilateral enlarged kidneys
II Renal agenesis / MCDK Absent or non-functional kidneys Classic Potter Syndrome
III ADPKD (adult type) Rarely severe in utero Uncommon fetal presentation
IV Obstructive uropathy (PUV) Cystic dysplasia from obstruction Posterior urethral valves
Non-renal PPROM / Placental insufficiency Occult fluid leakage; 50% of 2nd-trimester cases No renal malformation

Also: Renal tubular dysgenesis (RAS gene mutations) · 17q12 deletion syndrome

Pathophysiology

The Oligohydramnios Cascade

Deficient fetal
urine production
→
Severe
oligohydramnios
/ anhydramnios
→
Pulmonary
hypoplasia
Primary cause of death
Uterine wall
compression
→
Skeletal deformities
Limb contractures
→
Potter facies
Arthrogryposis

Critical window: 16–26 weeks' gestation — amniotic fluid essential for distal airway arborization.

Male fetuses predominantly affected. Associated cardiac defects frequent.

Pulmonary Hypoplasia

Three Interacting Mechanisms

🫁
1. Intrapulmonary Fluid Loss Reduced amniotic pressure → ↑ alveolar-to-amniotic gradient → excess lung liquid loss → arrested airway development. Tracheal ligation reverses effect experimentally.
🦴
2. Thoracic Compression ↑ Fetal spinal flexion → abdominal contents compress diaphragm → reduced lung expansion → further lung liquid loss.
🔬
3. Impaired Epithelial-Endothelial Development Oligohydramnios compromises cell size, type I epithelial differentiation, and angiogenesis in the developing lung.

Result: ↓ alveolar number · ↓ lung weight · inadequate gas exchange capacity at birth

Associated Anomalies

Concomitant Cardiac Defects

Structural heart anomalies occur frequently in Potter sequence. Fetal echocardiography is indicated at diagnosis.

33%
Ventricular Septal Defect
15%
Endocardial Cushion Defect
12%
Tetralogy of Fallot
12%
Patent Ductus Arteriosus

Also: Congenital pulmonary airway malformations (CPAM) · Breech presentation · Premature delivery

Clinical Features

Hallmark Findings of Potter Sequence

Potter Facies

  • Flattened nose
  • Recessed chin (micrognathia)
  • Large, low-set ears — deficient cartilage
  • Prominent infraorbital creases
  • Wide-set eyes (hypertelorism)
  • Mechanical compression etiology

Somatic Findings

  • Pulmonary hypoplasia — primary cause of death
  • Clubfeet (talipes equinovarus)
  • Joint contractures / arthrogryposis
  • Limb positioning abnormalities
  • FGR — wrinkled, redundant skin
  • Breech presentation common
Prenatal Diagnosis

Ultrasound & Adjunct Modalities

Modality Key Finding Clinical Role
2D Ultrasound Severe oligohydramnios / anhydramnios; empty renal fossae; absent bladder filling Primary screening modality
Color Doppler Absent renal arteries Confirms bilateral renal agenesis
Furosemide Challenge Failure of bladder filling after maternal IV furosemide Adjunct when kidneys not visualized
Fetal MRI Hypoplastic thoracic cage; renal anatomy Equivocal ultrasound findings
Chromosomal Microarray 17q12 deletion; AR conditions Genetic evaluation — all cases

SMFM Fetal Anomalies Consult Series #4 (2021) · Maternal AFP does not reliably discriminate renal vs. non-renal cases

Prognosis

Longitudinal Outcomes — Renal Oligohydramnios

22-year retrospective cohort · n = 131 fetuses · Nishi et al., J Pediatrics 2024

30%
Survived beyond neonatal period
35%
Termination of pregnancy
20%
Neonatal death
8%
IUFD
7%
Postneonatal death

Earlier GA at oligohydramnios onset: OR 1.16 (95% CI 1.01–1.37) for IUFD

Kaplan-Meier survival (all causes): 57% at 1 yr · 55% at 3 yr · 51% at 5 yr

Landmark Evidence

The RAFT Trial — JAMA 2023

Renal Anhydramnios Fetal Therapy Trial · Miller JL et al. · Johns Hopkins & Multicenter · JAMA 2023;330(21):2096-2105

82%
Survived ≥14 days & dialysis access placed (vs. 0% expectant)
35%
Survived to hospital discharge on long-term dialysis
<26w
Gestational age threshold for amnioinfusion initiation
"Serial amnioinfusions initiated before 26 weeks' gestation mitigated lethal pulmonary hypoplasia in newborns and was associated with survival to at least 14 days of life and placement of dialysis access in 82% of neonates." — Miller JL, Baschat AA, Rosner M, et al. JAMA. 2023
Intervention

Serial Amnioinfusion — Mechanism & Rationale

Transabdominal
amnioinfusion
<26 weeks
→
Restore amniotic
fluid volume
→
Mechanically stent
uterine cavity
→
Permit distal
airway development

Eligibility Criteria

  • Singleton pregnancy
  • Bilateral renal agenesis confirmed
  • Initiation before 26 weeks GA
  • Tertiary center with neonatology + nephrology
  • Patient declines termination

Neonatal Requirements

  • Immediate ventilatory support at birth
  • HFOV or ECMO if severe hypoplasia
  • Long-term hemodialysis (even VLBW infants)
  • Eventual renal transplantation
  • Disrupted RAAS — BP management
Management

Clinical Management Pathways

Palliative / Comfort Care

  • Standard prenatal care
  • No fetal monitoring in labor
  • Vaginal delivery preferred
  • Comfort care at birth
  • Rapid mortality: asphyxia / respiratory failure
  • Perinatal hospice consultation

Experimental / Aggressive

  • Serial amnioinfusions (tertiary center)
  • Intense fetal surveillance
  • Planned delivery at level IV NICU
  • MFM + Neonatology + Peds Nephrology coordination
  • Survival possible: up to 30–35%
  • Long-term dialysis & transplant required

Anhydramnios <22 weeks without intervention → 100% neonatal mortality expected

Counseling

Obstetrician Counseling Imperatives

🫧
Pulmonary Function is the Sole Determinant Preserving lung development in utero is the only modifiable factor for short-term neonatal survival.
📅
Gestational Age at Onset is Critical Earlier onset = significantly higher risk of IUFD (OR 1.16). Counsel accordingly at time of diagnosis.
⚖️
Three Options Must Be Presented Termination of pregnancy · Palliative neonatal care · Aggressive experimental management (amnioinfusion + dialysis).
🏥
Multidisciplinary Coordination Required If aggressive management selected: MFM + Neonatology + Pediatric Nephrology before delivery.
Genetics

Genetic Counseling Considerations

Condition Inheritance Recurrence Risk Testing
Isolated bilateral renal agenesis Multifactorial (most likely) Low; AR documented in familial cases Chromosomal microarray
Renal tubular dysgenesis Autosomal recessive 25% per pregnancy RAS gene panel (ACE, AGT, AGTR1, REN)
17q12 deletion syndrome De novo or AD Defined recurrence risk Microarray / FISH
ARPKD Autosomal recessive 25% per pregnancy PKHD1 sequencing

Genetic counseling indicated for all affected families · Prenatal testing available for defined recurrence-risk conditions

Neonatal Management

Ventilatory & Renal Support Strategy

Ventilatory Support

  • Survival requires sufficient lung volume for oxygenation
  • High-frequency oscillatory ventilation (HFOV) — first-line
  • ECMO — if severe but potentially viable hypoplasia
  • Conventional MV — adjunct
  • Refractory respiratory failure → mortality in classic BRA

Renal Replacement Therapy

  • Hemodialysis achievable in VLBW infants
  • Case reports confirm long-term maintenance possible
  • Peritoneal dialysis as bridge
  • Kidney transplant — long-term goal
  • RAAS disruption: BP management complex

Survival strictly depends on adequate lung volume — renal replacement alone cannot overcome lethal pulmonary hypoplasia

Clinical Pearls

Key Prognostic Determinants

⏱️
Gestational Age at Onset Single most critical prognostic factor. Earlier onset → higher IUFD risk (OR 1.16, 95% CI 1.01–1.37).
🫁
Degree of Pulmonary Hypoplasia Lung volume at birth determines short-term survival. Classic BRA without intervention → death within hours.
🏥
Level of Care & Intervention Tertiary center + serial amnioinfusions → 82% survive ≥14 days (RAFT). 35% survive to discharge.
⚖️
Underlying Etiology Non-agenesis renal oligohydramnios (PUV, ARPKD) may carry better prognosis than classic BRA.
Guidelines

Guideline & Evidence Alignment

Recommendation Source Evidence Level
Ultrasound + Color Doppler for diagnosis of BRA SMFM Fetal Anomalies Consult Series #4, 2021 Strong
Fetal MRI as adjunct for equivocal findings SMFM / Expert consensus Moderate
Chromosomal microarray for all Potter sequence SMFM / ACOG Strong
Serial amnioinfusion <26w for BRA (experimental) RAFT Trial — JAMA 2023 (Miller et al.) RCT Evidence
Multidisciplinary counseling — all cases ACOG / SMFM / Expert consensus Strong
Summary

Clinical Take-Home Points

Diagnosis & Pathophysiology

  • "Sequence" preferred over "syndrome" for non-BRA cases
  • Oligohydramnios 16–26w → pulmonary hypoplasia
  • Three mechanisms: fluid loss, compression, impaired development
  • Cardiac anomalies in up to 33% (VSD most common)
  • Chromosomal microarray for all cases

Prognosis & Management

  • Classic BRA without intervention: near-universal neonatal death
  • RAFT Trial: 82% survive ≥14d with serial amnioinfusions
  • 35% survive to discharge; all require long-term dialysis
  • Anhydramnios <22w without Rx → 100% neonatal mortality
  • Three counseling options must be explicitly offered

DoctorsWhoCode.blog · Maternal-Fetal Medicine · References: Dicker 1984 · Miller JAMA 2023 · Nishi J Pediatrics 2024 · SMFM 2021 · Scott 1995

← OpenMFM Library